ABCB1、CES1和CYP2C19基因多态性与氯吡格雷抵抗的相关性研究进展

Research Progress in the Correlation between ABCB1, CES1 and CYP2C19 Gene Polymorphisms and Clopidogrel Resistance

氯吡格雷是目前全球临床使用最为广泛的血小板受体抑制剂,但其抗血小板效应存在明显个体差异,部分病人服用常规剂量氯吡格雷后存在抵抗现象,甚至发生不良临床事件。多项研究表明,ABCB1、CES1和CYP2C19基因多态性对氯吡格雷抵抗的产生发挥重要作用。简介氯吡格雷体内吸收与代谢机制和氯吡格雷抵抗的定义,综述ABCB1、CES1和CYP2C19基因多态性对氯吡格雷抵抗的影响。

Clopidogrel is one of the most widely clinically used platelet receptor inhibitors in the world, but there exists significant individual difference in its anti-platelet effect. Clopidogrel resistance, even adverse clinical events, could be presented in some patients taking common doses of clopidogrel. Several studies have shown that ABCB1, CES1 and CYP2C19 gene polymorphisms play a key role in clopidogrel resistance. the mechanisms of in vivo clopidogrel absorption and metabolism and the definition of clopidogrel resistance were introduced. The impacts of ABCB1, CES1 and CYP2C19 gene polymorphisms on clopidogrel resistance were reviewed.